We asked Brian Wolpin, the presenter for yesterday’s plenary on the daraxonrasib pancreatic cancer study, about the sustained ...

With no licensed vaccines available to protect against the Ebola virus currently spreading in the Congo, efforts are underway ...

Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but ...

A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using ...

The FDA has missed a self-imposed deadline to ban the use of electrical shock devices in people with intellectual ...

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

Health insurers, providers, and consumer advocates praised the Trump administration’s long-awaited fixes to the No Surprises ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

Growing legislative scrutiny across multiple states targets the corporate structure underlying most direct-to-consumer ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is also the author of the morning Pharmalittle newsletter ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...